Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/03, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Ellex Medical Lasers Limited

ABN

15 007 702 927

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1  Class of +securities issued or to be issued

   Ordinary shares

2  Number of +securities issued or to be issued (if known) or maximum number which may be issued

   7,000,000 (from the placement announced 1st December 2016)

3  Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)

   Fully paid ordinary shares

+ See chapter 19 for defined terms.

04/03/2013
Appendix 3B
New issue announcement

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Ordinary shares - Yes

5 Issue price or consideration

$1.47

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

1. Develop sales growth in iTrack with development of USA headquarters.
2. Emerging leader in MIGS device market.
3. Increase surgeon engagement through clinical training and KOL's

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

No

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

N/A

6c Number of *securities issued without security holder approval under rule 7.1

N/A

+ See chapter 19 for defined terms.
### Appendix 3B
#### New issue announcement

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>**Number and *class of all <em>securities not quoted on ASX (including the <em>securities in section 2 if applicable)</em></em></td>
</tr>
<tr>
<td></td>
<td><strong>Number</strong></td>
</tr>
<tr>
<td></td>
<td>Nil</td>
</tr>
</tbody>
</table>

| 10 | **Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)** |

#### Part 2 - Pro rata issue

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td><strong>Is security holder approval required?</strong></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td><strong>Is the issue renounceable or non-renounceable?</strong></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>*<em>Ratio in which the <em>securities will be offered</em></em></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>**<em>Class of <em>securities to which the offer relates</em></em></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>*<strong>Record date to determine entitlements</strong></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td><strong>Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</strong></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td><strong>Policy for deciding entitlements in relation to fractions</strong></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td><strong>Names of countries in which the entity has security holders who will not be sent new offer documents</strong></td>
</tr>
</tbody>
</table>

*Note: Security holders must be told how their entitlements are to be dealt with.*

*Cross reference: rule 7.7.*

* See chapter 19 for defined terms.
Appendix 3B
New issue announcement

<table>
<thead>
<tr>
<th>Number</th>
<th>+Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nil</td>
<td>-</td>
</tr>
</tbody>
</table>

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

**Part 2 - Pro rata issue**

11 Is security holder approval required?

12 Is the issue renounceable or non-renounceable?

13 Ratio in which the +securities will be offered

14 +Class of +securities to which the offer relates

15 +Record date to determine entitlements

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17 Policy for deciding entitlements in relation to fractions

18 Names of countries in which the entity has security holders who will not be sent new offer documents

*Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

+ See chapter 19 for defined terms.
19 Closing date for receipt of acceptances or renunciations
Appendix 3B
New issue announcement

20 Names of any underwriters

21 Amount of any underwriting fee or commission

22 Names of any brokers to the issue

23 Fee or commission payable to the broker to the issue

24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

25 If the issue is contingent on security holders' approval, the date of the meeting

26 Date entitlement and acceptance form and offer documents will be sent to persons entitled

27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

28 Date rights trading will begin (if applicable)

29 Date rights trading will end (if applicable)

30 How do security holders sell their entitlements in full through a broker?

31 How do security holders sell part of their entitlements through a broker and accept for the balance?

+ See chapter 19 for defined terms.
Appendix 3B
New issue announcement

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 *Issue date

Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities

34 Type of *securities
(tick one)

(a) ☑ "Securities described in Part 1

(b) ☐ All other *securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 ☐ If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders

36 ☐ If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 ☐ A copy of any trust deed for the additional *securities

* See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 7
Entities that have ticked box 34(b)

38 Number of *securities for which *quotation is sought

39 *Class of *securities for which quotation is sought

40 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another *security, clearly identify that other *security)

Number | *Class

42 Number and *class of all *securities quoted on ASX (including the *securities in clause 38)

* See chapter 19 for defined terms.
Quotation agreement

1  "Quotation of our additional *securities is in ASX's absolute discretion. ASX may quote the *securities on any conditions it decides.

2  We warrant the following to ASX.
   - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
   - There is no reason why those *securities should not be granted *quotation.
   - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

   - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.

   - If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

3  We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4  We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: [Signature]

Company secretary

Date: 8th April 2016

Print name: Maria Maieli

== == == == ==